


medicines
patent
pool


FACILITATING ACCESS TO HCV TREATMENT THROUGH PUBLIC HEALTH ORIENTED LICENSING

Greg Perry
Executive Director

First patent pool in public health

Aim: to facilitate access to affordable, quality-assured drugs in developing countries through public health oriented licensing







Product: Daclatasvir and combinations containing DCV (e.g. SOF/DCV)



Geographical Scope: 112 countries (including ~ 75 MICs)



Quality assurance: requirement to obtain approval from WHO PQ or stringent regulatory authority



Royalties: royalty-free licence




Transparency: licence public on MPP website

*10 MPP sub-licensees working on the development,
registration, manufacturing and/or distribution of DCV*



Two years after MPP licence with BMS, multiple generics will be filing DCV and SOF/DCV for approval by WHO Prequalification (PQ)





Product: Ravidasvir (product currently in clinical trials in Malaysia and Thailand)



Geographical Scope: complements DNDi's licence for a total of over 130 countries



Quality assurance: requirement to obtain approval from WHO PQ or stringent regulatory authority



Royalties: 4% and 7% depending on income level



Transparency: licence public on MPP website

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

Most comprehensive source of information on the patent and licensing status of medicines for HIV, TB and Hepatitis in low and middle income countries



Patent status data from over 110 low and middle income countries



Data exclusivity information from 15 countries



Covering 8 hepatitis C and 2 hepatitis B products



Information on all relevant licences in LMICs

www.medspal.org

Supported by:



www.medicinespatentpool.org
[@MedsPatentPool](https://twitter.com/MedsPatentPool)
www.medspal.org